Key Points
- Halozyme director Bernadette Connaughton sold 1,625 shares on June 1 at an average price of $66.21, totaling about $107,591. The sale was made under a pre-arranged Rule 10b5-1 trading plan and reduced her holdings by 3.59%.
- The company reported strong quarterly results, with Q1 EPS of $1.60, topping estimates of $1.54, and revenue of $376.71 million, up 42.2% year over year. Halozyme also reaffirmed its FY2026 EPS guidance of $7.75 to $8.25.
- Analysts remain generally bullish on HALO, with several firms raising price targets and the stock holding a consensus rating of “Moderate Buy.” The average price target now stands at $80.67, above the recent trading price near $66.
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $66.21, for a total transaction of $107,591.25. Following the sale, the director owned 43,669 shares of the company's stock, valued at approximately $2,891,324.49. The trade was a 3.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Bernadette Connaughton also recently made the following trade(s):
- On Friday, May 1st, Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $63.48, for a total transaction of $103,155.00.
Halozyme Therapeutics Price Performance
HALO stock opened at $66.28 on Wednesday. The firm has a 50 day moving average of $66.24 and a 200-day moving average of $68.75. Halozyme Therapeutics, Inc. has a 12-month low of $51.06 and a 12-month high of $82.22. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. The company has a market cap of $7.86 billion, a price-to-earnings ratio of 23.84, a PEG ratio of 0.28 and a beta of 0.88.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. During the same period last year, the firm earned $1.11 EPS. The company's revenue for the quarter was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, equities analysts expect that Halozyme Therapeutics, Inc. will post 7.6 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of equities research analysts have recently issued reports on the stock. HC Wainwright lifted their price target on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the company a "buy" rating in a research report on Wednesday, April 29th. Wall Street Zen raised shares of Halozyme Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, May 16th. Benchmark raised their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a "buy" rating in a research note on Thursday, February 19th. TD Cowen reissued a "buy" rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Finally, Weiss Ratings raised shares of Halozyme Therapeutics from a "hold (c)" rating to a "buy (b-)" rating in a research note on Tuesday, May 12th. Seven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $80.67.
Get Our Latest Stock Analysis on HALO
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the business. Alpine Woods Capital Investors LLC purchased a new position in shares of Halozyme Therapeutics during the 1st quarter worth approximately $281,000. Glenmede Trust Co. NA increased its stake in shares of Halozyme Therapeutics by 22.4% during the 1st quarter. Glenmede Trust Co. NA now owns 146,717 shares of the biopharmaceutical company's stock worth $9,482,000 after purchasing an additional 26,851 shares in the last quarter. Argent Capital Management LLC increased its stake in shares of Halozyme Therapeutics by 52.2% during the 1st quarter. Argent Capital Management LLC now owns 9,054 shares of the biopharmaceutical company's stock worth $585,000 after purchasing an additional 3,104 shares in the last quarter. BankChampaign National Association purchased a new stake in Halozyme Therapeutics in the 1st quarter worth approximately $228,000. Finally, Western Wealth Management LLC purchased a new stake in Halozyme Therapeutics in the 1st quarter worth approximately $229,000. 97.79% of the stock is owned by hedge funds and other institutional investors.
About Halozyme Therapeutics
(
Get Free Report)
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
